Hot Investor Mandate 1: China-Based Family Office Seeks Global Investment and In-Licensing Opportunities with Focus in USA & UK

A venture capital fund/family office based in Hangzhou, China currently manages two venture funds in addition to a number of private capital accounts through which investments are made – these two funds focus on life sciences. The firm primarily makes equity investments in early-stage rounds ranging from $1 million initially; for later-stage to pre-IPO companies, the firm looks to make initial equity investments ranging from $3-5 million. The firm looks for companies located around the globe, with a preference in the US and Europe (UK). Currently, the firm is also actively seeking in-licensing opportunities in biotech innovations that has a China angle. The firm is actively looking for investment opportunities.

The firm is a flexible and opportunistic investor and will consider therapeutics, medical devices, and diagnostics. The firm is open to all kinds of sectors and indications. For therapeutics, the firm has specific focuses on novel candidates for disease, PD1-base approaches, gene therapy, oncology, cardiovascular diseases, and small molecules. For medical devices, the firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is also interested in diagnostics although this area is less of a focus. In terms of therapeutics, the firm will look at products of pre-clinical stage and later stages from phase II to phase III. Regarding medical devices, the firm will invest at any stage of development.

The firm is looking for private companies only. The firm typically has no specific requirements for the management team, but this depends on how much the firm invests. The firm looks to take a board seat following the investment and is comfortable acting as both a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Japanese PE Looks Globally for Early-Stage Life Sciences Innovations

A private equity firm headquartered in Tokyo, Japan with multiple offices throughout North America and Asia is currently making new investments from three main funds: SV5 Series (JPY 75 billion; 2016 vintage), Asia Technology Fund VI (USD 150 million; 2013), and Technology Partners V (USD 260 million; 2012). The firm has about JPY 429 billion AUM (USD 4.3 billion). The firm has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the USA and Japan.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Global Chemical Company Launches Strategic VC Arm to Invest in Devices and Diagnostics

An Asia-based global chemical company that serves the chemical, petrochemical and bioscience markets among other markets, has recently started a corporate venture initiative with a $300M budget to make strategic investments into both pre and post-commercial companies. The group is flexible in terms of structuring investments and may employ equity investments, M&A and licensing agreements. The group targets investment sizes from $100k – $5M for early stage companies and $10M – $50M for commercial-stage companies.

In terms of the healthcare and life science sectors, the group is most interested in companies working in diagnostics and research tools. The group is particularly interested in clinical diagnostics including IVDs and next generation platforms (NGS, liquid biopsy, LC-MS, point-of-care testing, digital PCR), separation media and connected devices and wearable medical sensors. The group is also interested in advanced materials including materials for secondary batteries, thin-film for electronic devices, separation (inorganic/organic/polymers) and composites. The group is agnostic to indication area, but has a particular interest in cancer, metabolic (including diabetes) and kidney disorders as well as reproductive health.

The group has no strict company or management team requirements and invest in both early and later stage opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Switzerland Corporate VC Arm Seeks to Invest in USA and Europe with Strong Focus in Digital Health Technologies

A corporate venture capital arm of a Switzerland-based corporate manages a strategic fund aligned with the corporate’s strategy, focusing on oncology and infectious diseases. The fund serves two main purposes: to improve the patient journey (quality of life) and to improve drug development (patient recruitment, best responders, combination therapy). This is a $150M fund and invests in the range of $1M – $10M per company. The firm typically seeks to participate in Series A/B rounds, and is currently seeking 1-3 new equity opportunities a year. The firm supports the in-licensing activities of the corporate in the EU and U.S.

The firm is mainly seeking digital health and healthcare IT technologies, and additionally therapeutics and diagnostic proposals that relate to oncology and infectious diseases to support the corporate’s activities.

Within healthcare IT, the firm is seeking technologies at precommercial or commercial stage with potential customer traction that may use AI to integrate different data sources for patient monitoring, clinical decision support systems, digital therapeutics and solutions to improve drug development such as tools to optimize and accelerate patient recruitment and clinical development in general.

Within diagnostics, the firm is seeking molecular diagnostic tools in development stage which are strongly innovative (e.g. liquid biopsy) and have smart data components.

The firm is seeking oncology and infectious disease therapeutics to in-license.

The firm is very active and supportive with their portfolio companies. The firm typically seeks a board seat, and at times, also an observer seat. The firm is looking for experienced management team in the domain of focus and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

What Makes A Good Innovation Challenge Application?

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Every RESI Conference, LSN holds a fun life science competition – the Innovation Challenge. Thirty early-stage fundraising companies with top-tier life science technology exhibit in a poster-board format for a chance to pitch to investor attendees one-on-one and place as one of three winners voted by conference attendees. Out of our hundreds of applications, how do we choose the top thirty? As the Innovation Challenge application deadline draws near (it is tomorrow folks!), the LSN scientific review team has compiled a list of what we look for in a company and its application.

While the following surrounds the Innovation Challenge application itself, the criteria and the tips we provide are also guidelines for companies to use for their fundraising process. Much of our evaluation and the questions we ask are based on standard criteria that entrepreneurs will face when speaking with investors.

What makes a high-score company?

The LSN scientific review team uses a detailed rubric with a 200-point scoring system. Our evaluation process is based not only on scientific merit, but also on how ready the company is to present to an investor (“investor-readiness”). A perfectly scored company would have a transformational technology that can achievably address a high unmet need using a differentiable novel approach or target. Alongside high innovation, differentiation, unmet need, and market fit, the 200-point company would have a broad IP position, an experienced management team and CEO with top-tier advisors, and strategic alliances with manufacturing and clinical partners. The company will also receive high marks for having what we call “investor-ready” marketing material (executive summary, pitch deck, website).

Application Tips

Clearly describe your technology.

Like any marketing material, you need to be clear. Be sure you understand and answer the questions fully. The team has seen unclear responses as to what a company’s technology is and its significance in improvement.

Be honest with your answers.

The team frequently reviews applications that state they have no competitors in the space, when the honest answer is, there are. Novel products do have competitors before them, for established technology does exist in the indication your product targets. Be honest with whom your competitors are, and then address what the key differentiators are to your product. Even if your product is an incremental improvement, be honest and highlight this and it can still be attractive!

For example, competitors for your disease-modifying therapeutic may be symptom-treating therapeutics in the same indication that are either commercialized or being developed. You should identify these symptom-treating therapeutics and highlight your novel target approach that makes your product disease-modifying.

Explain your current standings in detail.

Outline everything you have in terms of your current standing, while also providing your outlook of where you hope to go. Avoid ambiguous statements such as, “CEO is an experienced entrepreneur”. Instead, provide details that highlight the CEO’s experience – years as an entrepreneur, number and names of companies exited, background expertise, etc.

Provide near-future and long-term horizons.

If you do not have certain criteria, such as a strategic alliance or IP, it’s OK. State your current standing and provide what steps you are currently taking to reach that milestone. For Alliances and Collaborations, state your verbal relationships; for IP status, state how many you have filed or are planning to file. Providing us your strategy is better than a simple yes or no.

Put in a balanced effort.

You should not spend 5 minutes on this application, and neither should you spend 5 hours. Your answers should be brief, as well as detailed – we have received hasty, effortless applications in which we quickly discard with a low score. On the other hand, you also shouldn’t spend an excessive amount of time on the application, as these are all straight-forward questions that you should be comfortable in answering and have down pat. Remember, as your executive summary should answer all these questions alone, this application is the backbone of our evaluation process and essentially your executive summary to us.

Send us your marketing material.

If you have marketing material, send it. This includes your pitch deck, executive summary, website, videos – any supplemental material that can boost our understanding of your technology and whether your company is investor-ready. The application provides limited space – while this forces you to get straight to the point, supplemental material explains what an application cannot (i.e. figures, graphs, pipeline, non-confidential data, etc.).

Overall, applying for the Innovation Challenge is great practice for fundraising companies. For those who have yet to apply, be sure to take note of these suggestions and apply here before midnight tomorrow!

RESI JPM 2018: Agenda Announced

By Jessica Yang, Investor Research Analyst, LSN

Biotech and medtech industry executives are drawing up their itineraries for January’s healthcare conference week in San Francisco, and over a thousand attendees are expected to join Life Science Nation for our Redefining Early Stage Investments (RESI) Conference in San Francisco on January 9th!

LSN would now like to announce the agenda for RESI San Francisco. Our event will provide a full day of investor panels and workshops devoted to early-stage life science investment topics. RESI features four tracks of content, including the RESI Asia-North America track, which offers attendees the chance to hear directly from investors and strategic partners from across the Pacific who are seeking North American innovation. These panels will be a must-see for any fundraising entrepreneur in the life science sector.

In addition to RESI’s recurring core sector panels Early Stage Therapeutics, Medical Device Investors, Diagnostics and Healthcare IT, RESI San Francisco will also feature the Big Data & Healthcare Panel. The big data space has increasingly become exciting with its potential to transform healthcare through its cross-correlation to broad applications. In addition, LSN will be bringing back the highly popular panel on Genomics. Genomics is becoming a major technology for life science investment, and the panel will provide the opportunity to learn about the kinds of genomic-related breakthrough that investors are looking to back, and the challenges of investing in the genomics field. Be sure to register now for these tremendous opportunities to learn how investors think about your space.

Why Do So Many Investors Come To RESI? It’s Not Only To Meet Startups

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Life Science Nation (LSN) brought the Redefining Early Stage Investments (RESI) conference to life four years ago with the vision of creating a circuit of events focused on bringing together life science entrepreneurs and early-stage investors, from a wide variety of categories, based on mutual fit. One of the most prominent themes we’ve witnessed, after 15 RESI conferences in cities across North America, is the complexity and evolution of the early-stage healthcare ecosystem. The variety of capital sources, strategic partners and other critical stakeholders in the industry has created an environment where investment groups/firms find tremendous value in working together to finance, scale and exit companies.

Investors are primarily drawn to RESI by the large number of top tier startups that attend, but RESI has become much more than a place for investors to find startups and vice versa. While the bulk of the meetings that take place at RESI are between investors and entrepreneurs, RESI also provides a venue for investors to find the newest capital sources, complimentary co-investors and foster relationships with a range of otherwise strategic and exit partners.

We took a look at the partnering meeting data, and discovered that in terms of who meets with whom at RESI conferences, investor-to-investor partnering meetings represent the third largest category, after investor-to-startup meetings and startup-to-service provider meetings. Driven by the unique nature of the early-stage healthcare landscape, LSN’s dedication to bringing in a diverse pool of capital providers makes RESI a must-attend event for all investors and entrepreneurs alike.

We asked some regular attendees their thoughts on RESI’s capacity to help investors connect, and here’s what they said:

“RESI provides a dynamic and fast-paced setting for strategic investors, venture capitalists and entrepreneurs to explore the latest innovations that will disrupt conventional healthcare and redefine the means by which we enable health and wellness in our communities.  As strategic investors, we are particularly interested in RESI to find opportunities to build more patient-centric care models, pilot scalable and efficient delivery models and identify business opportunities to successfully tackle the ‘big’ challenges in healthcare.”
– Eric Louie, CMO, Healthbox Global Partners

“I have attended multiple RESIs over the years in SF, NYC and Toronto.  Each has given me a unique perspective on the ecosystem of the area and allowed me to connect with like-minded co-investors and strategic partners.  I will definitely be at the RESI in SF this January.”
–Sam Ifergan, President & CEO, iGan Partners

“The RESI conference platform is a highly productive forum for me to engage with both early-stage entrepreneurs and investors. The 30-minute format allows for just enough time to gain a high level understanding of an opportunity or an investors profile. I attend several each year and recommend highly when speaking with both founders and co-investors.”
–Sean Kearney, Managing Director, Fosun Group

Qualified investment firms can receive up to two complimentary passes to attend the upcoming RESI conference in San Francisco on January 9, 2018. The previous RESI @ JPM event hit capacity two weeks prior to the date of the conference. Please reach out to research@lifesciencenation.com to request registration for the event and take advantage of the RESI partnering system to secure meetings and get the most out of your Tuesday during JPM week.